



The most selective LC-EC applications for Clinical & Diagnostics analysis

**Catecholamines**

Serotonin  
Metanephrines  
VMA  
HVA  
5-HIAA

**PET imaging tracer**

Fluorodeoxyglucose (FDG)  
FDG impurities

**Sulfides**

Homocysteine  
Glutathione  
Disulfides

**Vitamins, minerals**

A, C, D, E, and K  
Iodide  
Q10, Ubiquinols

# Compilation of Clinical Applications

- **ALEXYS Analyzers in Clinical Analysis**
- **Optimized for performance**
- **Dedicated system solutions**

Analysis of bodily fluids in clinical laboratories is of great diagnostic importance to discover diseases in an early stage. A number of tumor and cardiovascular markers have been analyzed using dedicated ALEXYS Analyzers. Special attention has been paid to sample throughput, reliability and robustness of analysis.

A selection is presented of different application notes from the work of a few of our many users. These notes demonstrate the versatility of our analyzers in different experimental conditions.

## Contents

- 213-016 Serotonin in Plasma
- 213-011 Free Catecholamines in urine
- 213-010 Total catecholamines in urine
- 213-008 VMA, HVA and 5-HIAA in urine
- 213-007 Plasma Catecholamines
- 213-004 Metanephrines in Urine
- 212-003 Iodide in urine
- 211-003 Homocysteine in plasma
- 218-006 Ascorbic acid in human plasma
- 218-005 Vitamin K in plasma
- 218-001 Q10, ubiquinols, Vit E, and  $\beta$ -carotene in LDL
- 218-004 Fat soluble vitamins A, D, E and K



Figure 1: ALEXYS Clinical Analyzer.



## Serotonin in human plasma

### Introduction

Within the circulation more than 99% of serotonin (5HT) is stored in blood platelets. Increased concentrations in circulating 5HT have been implicated in migraine, schizophrenia, carcinoid syndrome, essential hypertension, Huntington's chorea and Duchenne's dystrophy (see 1). In addition, changes in 5HT function in platelets seem to reflect central nervous system functions of 5HT, so platelet 5HT function is also proposed as a peripheral model for 5HT in the CNS (2).

LCEC provides a highly sensitive and specific means to analyse the fate of 5HT in biological matrices. However, collection and the preparation of blood samples without disturbing the massive but very delicate platelet pool requires great care to prevent leakage from this pool (2, 3). This can be accomplished by centrifuging at a low and high speed subsequently to separate the platelets from the remainder of the blood without disturbing the platelet integrity.

### Method

Venous blood samples (10 ml) are collected from the cubital vein in EDTA tubes (10 ml, 0.12 ml EDTA, 15%). Samples are centrifuged (90 g) at 4°C during 20 min and the supernatant, containing platelet-rich plasma is transferred to 8 ml tubes and centrifuged again (2500 g) at 4°C during 20 min. The supernatant is transferred and frozen (-20°C). Prior to analysis the samples are thawed, diluted 1.4 times with HPLC buffer without ion-pairing agent, the internal standard N-methyl-5HT(nMet), 10 µl, 0.22 µg/ml and TCA (65 µl, 3.1 M) are added and this mixture is centrifuged (1500 g, 20 min, 4°C). A volume of 20 µl of the supernatant is injected into the LCEC system.

Table 1

Set-up	
Column	Merck Superspher Select B (125 x 4 mm ID), pre-column Select B (10 mm)
Flow rate	0.7 ml/min
Mobile phase	50 mM citrate, 50 mM acetate (pH 4.0), 0.96 mM SOS, 0.54 mM EDTA and 4.5% ACN (v/v)
Temperature	30°C
Icell	0.1 – 0.5 nA
Flow cell	VT-03, 3 mm glassy carbon WE
E-cell	600 mV vs. Ag/AgCl sat'd




Figure 2: Chromatogram of 5-HT (1) and nMet (2, IS) in human plasma. Concentration is 1 ng/ml. Courtesy: J.C.M. Schouten - Verhagen et al., Rijngest Group, Oegstgeest.

### References

1. P.C. Tagari, D.J. Boullin and C.W. Davies, Clin. Chemistry 30 (1984) 131 – 135.
2. C.M. Middelkoop, G.A. Dekker, A.A. Kraayenbrink, and C. Popp-Snijders, Clin. Chem., 39, 1993, 1675-1678.
3. M. Picard, D. Olichon and J. Gombert, J. Chromatogr. 341, 1985, 445-451.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## Free catecholamines in urine

### Introduction

The catecholamines noradrenaline (NA) and adrenaline (A) play an important role in sympathetic activity, and sympathetic dysfunction may be reflected in variable changes in catecholamine production and excretion (1). In clinical laboratories they are measured mainly for the diagnosis and follow-up of catecholamine producing tumours like pheochromocytoma and neuroblastoma and, to a lesser extent, also to diagnose orthostatic hypotension. Although pheochromocytomas are usually benign, confirmation of diagnosis is important because of the harmful effects of increased circulating catecholamines, such as severe hypertension. The definitive diagnosis of pheochromocytoma rests primarily on the measurement of catecholamines in blood or urine, or of their urinary metabolites (see Application Notes 213-008 and 213-004). LCEC is known to be a fast and reliable method for the analysis of urinary catecholamines and metabolites.

### Method

An equilibrated ion exchange column is used for each sample. The pH of the urine is adjusted to pH 6.5 by NaOH. EDTA (0.1%) and the internal standard (dihydroxybenzylamine, DHBA, 0.01 mg/ml) solution are added to 3.0 ml urine and this sample is applied to the cation exchange column (Biorad, part no. 1956017). Possible interferences are removed by rinsing the columns with water and the catecholamines are eluted with boric acid (4% W/V). A 20 µl aliquot of the sample is injected and separation and quantitation are achieved by a reversed phase column and an electrochemical detector respectively. The recovery percentage is calculated by comparing the peak areas of the internal standard DHBA added to the urine sample with a standard sample of DHBA also comprising NA, A and DA ('external standard'). It is assumed that the recovery percentages for NA, A and DA are the same as for DHBA and hence this loss is corrected for all 3 catecholamines.

Table 2

Set-up	
Column	Supelco LC-18, 150 x 4.6 mm, 3 µm
Flow rate	1.0 ml/min
Sample	20 µl
Mobile phase	Chromsystems catecholamine buffer
Temperature	30°C
E-cell	600 mV (vs. Ag/AgCl sat'd KCl)




Figure 3: Analysis of 190 nmol/l NA (1), 23 nmol/l A (2), 83 nmol/l DHBA (3) and 1.1 µmol/l DA (4). Courtesy: Dr. C. Popp-Snijders, Endocrine laboratory, Free University Hospital, Amsterdam, The Netherlands.

### References

1. B. Kagedal and D.S. Goldstein, J. Chromatography 429 (1988) 177-233.
2. P.E. Graham, G.A. Smithe, G.A. Edwards and L. Lazarus, Ann. Clin. Biochem. 30 (1993) 129-134.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## Total catecholamines in urine

### Introduction

The catecholamines noradrenaline (NA) and adrenaline (A) play an important role in sympathetic activity, and sympathetic dysfunction may be reflected in variable changes in catecholamine production and excretion (1). In clinical laboratories they are measured mainly for the diagnosis and follow-up of catecholamine producing tumours like pheochromocytoma and neuroblastoma and, to a lesser extent, also to diagnose orthostatic hypotension. Increased levels of catecholamines are associated with hypertension, however, pheochromocytomas are responsible for only 0.1 % of cases of hypertension. Although usually benign, confirmation of diagnosis is important because of the harmful effects of increased circulating catecholamines. The definitive diagnosis of pheochromocytoma rests primarily on the measurement of catecholamines in blood or urine, or of their urinary metabolites (see Application Notes 213-008 and 213-004). LCEC is known to be a fast and reliable method for the analysis of urinary catecholamines and metabolites.

### Method

Prior to extraction on an equilibrated ion exchange column urine samples (about 12 ml, acidified with HCl conc to pH 1) are hydrolysed by boiling (100°C). After hydrolysis the pH of the urine is adjusted to pH 6.5 by NaOH. EDTA (0.1%) and the internal standard (dihydroxybenzylamine, DHBA, 0.01 mg/ml) solution are added to 3.0 ml urine and this sample is applied to a cation exchange column (Biorad 1956017). Possible interferences are removed by rinsing the columns with water and the catecholamines are eluted with boric acid (4% W/V) A 20 µl aliquot of the sample is injected in duplicate and separation and quantitation are achieved by a reversed phase column and an electrochemical detector resp. The recovery percentage is calculated by comparing the peak areas of the

internal standard DHBA added to the urine sample with a standard sample of DHBA also comprising NA, A and DA ('external standard'). It is assumed that the recovery percentages for NA, A and DA are the same as for DHBA and hence this loss is corrected for all 3 catecholamines.




Figure 4: Analysis of 190 nmol/l NA (1), 23 nmol/l A (2), 83 nmol/l DHBA (3) and 1.1 µmol/l DA (4). Courtesy: Dr. C. Popp-Snijders, Endocrine laboratory, Free University Hospital, Amsterdam, The Netherlands.

Table 3

Set-up	
Column	Supelco LC-18, 150 x 4.6 mm, 3 µm
Flow rate	1.0 ml/min
Sample	20 µl, extracted with Chromsystems ion exchange columns
Mobile phase	Chromsystems catecholamine buffer
Temperature	30°C
E-cell	600 mV (vs. Ag/AgCl sat'd)
I-cell	ca. 0.8 nA

### References

1. B. Kagedal and D.S. Goldstein, *J. Chromatography* 429 (1988) 177-233.
2. P.E. Graham, G.A. Smithe, G.A. Edwards and L. Lazarus, *Ann. Clin. Biochem.* 30 (1993) 129-134.
3. I.J. Kopin, *Pharmacol. Reviews* 37 (1985), 333-364.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## VMA, HVA and 5-HIAA in urine

### Introduction

The catecholamines dopamine, noradrenaline and adrenaline have a variety of important physiological functions in the central and peripheral nervous system. They are primarily inactivated by (re-)uptake into the nerve endings. Up to 90% of the originally released neurotransmitter is recaptured in this fashion. Catecholamines entering the plasma are degraded rapidly by catechol- O-methyl transferase to metanephrines. The further metabolic pathway via monoamineoxidase and aldehyde dehydrogenase leads to the end products vanillyl-mandelic acid (VMA) and homovanillic acid (HVA).

Tumour diseases of catecholamine synthesising tissue or catecholamine dependent tissue of the nervous system are associated with increased production of the neurotransmitters resulting in characteristic changes in the urinary excretion profile of the metabolites.


Determination of the serotonin metabolite 5-hydroxy-indoleacetic acid (5-HIAA) is particularly relevant for the diagnosis of carcinoid syndrome, a tumour of the enterochromaffin cells in the small intestine which leads to an increased serotonin production.

### Method

The sample pre-treatment consists of a liquid-liquid extraction with back extraction into phosphate buffer. Urine samples (5 ml) are acidified by adding 50 µl concentrated acetic acid. A volume of 0.5 ml acidified urine is mixed with 0.5 ml water, 0.5 ml internal standard (iso-VMA and 5-HICA, 70 nmol/l) and 1 g of NaCl. After addition of 2.5 ml ethylacetate, the mixture is vigorously shaken and centrifuged. A volume of 2 ml of the organic layer is transferred to a clean tube and 2 ml of phosphate buffer (200 mmol/l, pH=7) is added. After vigorously shaking and centrifugation the organic layer is removed and 50 µl of the aqueous layer is added to 3 ml of mobile phase. An aliquot of 20 µl is used for injection into the HPLC.

**Table 4**

Set-up	
Column	PhaseSep S3 ODS2, 100 x 4.6 mm, 3 µm, 20
µl injection	1.0 ml/min
Flow rate	1.0 ml/min
Mobile phase	Phosphoric acid 100 mM, citric acid 100 mM, pH 3.0 with KOH, EDTA 20 mg/l, octane sulphonic acid 400 mg/l, MeOH 6%
Sample	liquid-liquid extract of 24 h urine
Temperature	ambient
E-cell	900 mV (vs. Ag/AgCl sat'd)
I-cell	ca. 10 nA



**Figure 5:** Analysis of VMA, HVA and 5-HIAA in human urine. Peaks are: 1: VMA (26.7 µmol/l), 2: iso-VMA (IS), 3: 5-HIAA (66.4 µmol/l), 4: 5-HICA (5-hydroxyindolecarboxylic acid, IS), and 5: HVA (66.4 µmol/l). Courtesy: Dhr. J. van der Kolk, Clin. Chem. Lab., Bethesda Hosp., Hoogeveen, The Netherlands.

### References

1. B. Kagedal and D.S. Goldstein, *J. Chromatography* 429 (1988) 177-233.
2. P.E. Graham, G.A. Smithe, G.A. Edwards and L. Lazarus, *Ann. Clin. Biochem.* 30 (1993) 129-134.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## Plasma catecholamines

### Introduction

The catecholamines dopamine, noradrenaline and adrenaline play an important role in information transmission and regulation of metabolism in the body. Quantitative analysis of catecholamines is diagnostically important in a number of disease states such as hypertension, Parkinson's disease, schizophrenia, epilepsy etc. Of all detection methods available for the determination of catecholamines, HPLC with electrochemical detection is one of the most widely used. It is highly sensitive, selective and easy to apply.

### Method

Samples of biological origin require a purification step before HPLC analysis. Often used pre-treatment procedures are ion-exchange, extractions using alumina (Al<sub>2</sub>O<sub>3</sub>) or diphenyl borate ethanolamine (DPBEA). A number of methods have been developed and have been reviewed extensively [1, 2].

In this application a DPBEA extraction is used. The principle of this extraction is based on a complex formation between borate and the catecholamine diol at alkaline pH. DPBEA is dissolved in phosphate buffer at pH 8. The resulting ion pair is extracted in an organic phase (heptane). This extraction step is followed by a second extraction into an aqueous phase (80 mM acetic acid), and injection into an HPLC system.

The HPLC system consists of a reversed phase column with an ion-pair added to the mobile phase (Table I). The retention of polar amines such as noradrenaline is selectively affected by the ion-pair concentration, acidic sample constituents are selectively affected by the pH, while the modifier percentage affects both. Optimisation of resolution is therefore done by variation of these three parameters.

Table 5

Set-up	
Column	C18, 3 µm, 100 x 2.0 mm
Flow rate	0.2 ml/min
Mobile phase	Ammonium acetate 50 mM, glacial acetic acid 1.25%, sodium dodecyl sulphate 0.347 mM, EDTA 0.27 mM, 25% methanol
Injection	20 µl
Temperature	32.5 °C
E-cell	600 mV (vs. Ag/AgC, satd')




Figure 6: Analysis of human plasma after liquid-liquid extraction with DPBEA/Heptane. On-column amounts are: 1. norepinephrine: 31 pg, 2. epinephrine: 2.9 pg, 3. DHBA (IS): 200 pg, 4. dopamine: 1.5 pg. Plasma concentrations are: norepinephrine 386 pg/ml, epinephrine: 36 pg/ml, dopamine: 15 pg/ml. Courtesy: Ing. G. Alberts, Dept. of Int. Med. I, Univ. Hosp. 'Dijkzigt', Rotterdam, The Netherlands

### References

1. F. Ponzio, G. Achilli and C. Perego, in *Electrochemical detection in medicine and chemistry* (Ed. Parvez et al.), p. 307 - 329, 1987 VNU Science Press, Utrecht, The Netherlands.
2. E. Gelpí, in *Advances in Chromatography* (Eds. J.C. Giddings, E. Grushka and P.R. Brown), vol. 26 (1987) 321 - 391

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## Metanephrines in urine

### Introduction

Normetanephrine, metanephrine and 3-methoxytyramine are degradation products of noradrenaline, adrenaline and dopamine respectively. These metanephrines are formed by methylation of catecholamines by the enzyme catechol-o-methyltransferase. The metabolites are released into the blood stream and excreted mainly via the kidneys. The urinary excretion of catecholamines and their metabolites is an index of the activity of the sympathetic nervous system and allows diagnostic inferences in certain diseases.

The principal diagnostic test for diseases such as pheochromocytoma, neuroblastoma and ganglioneuroma, is measurement of urinary catecholamines and the acidic metabolites vanillylmandelic acid and homovanillic acid. However for reliable diagnosis further differential investigations are essential. Including the excretory profile of the metanephrines in the diagnostic consideration of nervous system tumours decreases the incidence of false negative results.


### Method

The major fraction of the metanephrines is excreted in conjugated form, either as glucuronides or sulphates. Since sample preparation on an ion exchange column isolates only the unconjugated forms, prior acid hydrolysis is essential.

After addition of internal standard, urine samples are acidified and hydrolysed by boiling. Metanephrines are isolated by ion exchange chromatography and analysed by ion pair chromatography with electrochemical (EC) detection [1].

Table 6

Set-up	
Column	PhaseSep S3 ODS2, 100 x 4.6 mm, 3 µm, 20 µl injection
Flow rate	0.80 ml/min
Mobile phase	Phosphoric acid 100 mM, citric acid 100 mM, pH 3.0 with KOH, EDTA 20 mg/l, octane sulphonic acid 400 mg/l, MeOH 6%
Sample	acid hydrolysate of 24 h urine (cation exchange + anion exchange extract)
Temperature	ambient
E-cell	875 mV (vs. Ag/AgCl, sat'd)
I-cell	ca. 5 nA



**Figure 7:** Analysis of human urine. Peaks are: 1: normetanephrine (0.9 µmol/l), 2: metanephrine (8.2 µmol/l), 3: hydroxymethylbenzylamine (IS), and 4: 3-methoxytyramine (0.5 µmol/l). Courtesy: Dhr. J. van der Kolk, Clin. Chem. Lab., Bethesda Hosp., Dr. G.H. Amshoffweg 1, 7909 AA Hoogeveen, The Netherlands.

### References

1. R.N. Gupta, Clin. Chem. 36 (1990) 538-540..

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb



## Iodide in urine

### Introduction

A method for the determination of iodide is developed using electrochemical detection (ECD) with a silver working electrode (WE). The method consists of ion exchange chromatography using a phosphate/citrate buffer at pH 6.5, followed by amperometric detection at 0.15 V. Detection limit of iodide is 0.2-1 µmol/L (25 - 127 ng/mL) depending on the column performance. Reproducibility of the determination of iodide is concentration depended. At 50 µM RSD in peak area's and heights was better than 2%. Below 1 µM the RSD values increased to 10 – 22 %.

### Method

The HPLC system consists of a anion exchange column with a phosphate/citrate mobile phase (Table I). The use of halide ions such as chloride and bromide must be avoided as they are reactive towards the silver electrode, causing a high background current and decreased sensitivity.

Di-sodium phosphate and citric acid (both 10 mM) are dissolved in 800 mL water, pH is set to 6.5 with NaOH and water is added to 900 mL. Finally 10% methanol (100 mL) is added. Determination of analytes in complex matrices such as urine or plasma is often complicated by sample pre-treatment procedures to improve the selectivity of a method. Without suitable pretreatment co-eluting peaks make reliable and reproducible analysis impossible.

An exception is the determination of iodide in urine. Due to the selectivity of the silver working electrode, urine could be injected directly. After dilution and filtration over a 0.2 µm membrane filter, urine samples have been injected onto the analytical column and analysed.

Table 7

Set-up	
Column	ALD-510 anion exchange column, 100 x 4.6mm, 7µm
Flow rate	1.3 mL/min
Mobile phase	Na <sub>2</sub> HPO <sub>4</sub> and citric acid (both 10 mM), pH set to 6.5 with NaOH, 10 % MeOH.
Temperature	35 °C (separation & detection)
Sample	urine is diluted (10x) and membrane filtrated (0.2 µm filter)
Range	500 nA/V
I-cell	30 - 50 nA
E-cell	50 mV vs HyREF




Figure 8: Regression line of standard addition analysis of iodide in diluted and filtrated urine (see results in Fig. 2). Line:  $Y = 76.6 + 180.9B$ ,  $r=0.9996$ .




Figure 9: Standard addition analysis of iodide in diluted (factor 10) and filtrated urine using ECD with a silver working electrode (20 µL). From top to bottom: urine with addition of 5, 2.5, 1, 0.5 and 0 µmol/L potassium iodide. Peak height of iodide (at t = 10 min) corresponds to a concentration of 4 µmol/l in urine.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0077W	ALEXYS Iodide Analyzer
-----------	------------------------



## Homocysteine in plasma

### Introduction

Homocysteine is a strongly oxidising and toxic product of amino acid metabolic pathways and raised blood levels (homocysteinaemia) are an established risk factor for arteriosclerosis and coronary heart disease. Increases of 10-15 % in the level of homocysteine raise the risk of coronary heart disease and cerebral vascular incidents approximately 3 to 4 fold. The current HPLC methods, relying on derivatisation of homocysteine and fluorescence detection, are laborious and the fluorescence label is quite expensive.

Therefore, a highly sensitive, economical, reproducible and rapid method for the analysis of homocysteine in plasma by isocratic reversed phase LC with electrochemical detection (EC) has been developed. The detection limit with standards is 0.3 nmol/L, RSD in peak heights is better than 1% and homocysteine is eluted within 5 minutes. Recovery from plasma samples is nearly 100%.

### Method

About 70 % of homocysteine in plasma is bound to albumine, 30% is present as mono- or disulphide. Therefore, prior to determination of total homocysteine, disulphides are reduced and released from albumine by TBP (tri-n-butylphosphine).

The internal standard N-(2-mercapto propionyl)glycine (2MPG, 50 µL of 16 mg/L), and 50 µL of TBP are added to 200 µL of plasma. After 30 min of incubation at 4 °C 200 µL of trichloroacetic acid (TCA) is added, and vigorously shaken for 2 min. After incubation for 15 min at 4 °C, the mixture is centrifuged at 10,000 RPM for 10 min. A volume of 100 µL of supernatant is diluted to 5 mL with mobile phase and analysed by LC-EC.


A working potential of +600 mV is applied. Prior to each run a cleaning pulse of +1 V and -1 V both of 1 s is applied, followed by 5 minutes stabilisation. The linearity has been checked using concentrations of 20, 40, 60, 80 and 100 nmol/L. The detector response is linear in this range with a regression coefficient better than 0.998 and with a detection limit of 0.3 nmol/L.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

**Table 8**

Set-up	
Column	Spherisorb S3 ODS2, 4.6 * 100 mm, 3 µm
Flow rate	1 mL/min
Sample	20 µL
Mobile phase	0.15 mol/L phosphoric acid (1%), 2 mmol/L KCl, 10 mg/L OSA pH 1.75 (with NaOH).
Temperature	30°C
E-cell	600 mV (vs. ISAAC 2 mM KCl)
I-cell	1.90 nA



**Figure 10:** Chromatogram of 39 µmol/L homocysteine (1) and 98 µmol/L 2MPG (2) in plasma. Range setting is 5 nA/V. Courtesy: J. v.d. Kolk, Bethesda hospital, Hoogeveen [1].

### References

1. Determination of homocysteine, Standard operating procedure A.29 HCYS\_1, Bethesda Hospital, Hoogeveen, The Netherlands
2. Nicola C. Smith, Mark Dunnet, Paul C. Mills, Journal of Chrom. 673 (1995), 35-41.
3. G.H.J. Boers, Mediator 8(2), March 1997, 9-11

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4321	SenCell 2 mm Au HyREF



## Ascorbic acid in human plasma

### Introduction

Ascorbic acid (AA) is normally present in human as well as in animal plasma and tissue. The daily need is considered to be at least 70 mg and normal blood levels are between 28 and 85  $\mu\text{M}$ . For example, the analysis of AA in plasma of geriatric patients reflects the quality of feeding status of such patients. Since it is quite labile, accurate measurement of AA in biological matrices highly depends on a reliable method to stabilise AA (1, 2). So, if samples are stored without specific precautions auto-oxidation of AA may occur, even after 15 minutes, and erroneous measurements will result. It appears that dithiothreitol (DTT) and metaphosphoric acid (MPA) are quite effective as an aid for long-term stabilisation (up to one year) of AA in biological samples and, in addition, DTT appears to reduce dehydro-ascorbic acid (1, 2). The analysis with LCEC is very straightforward and highly reproducible with the use of hydrochinon as internal standard. The runtime is determined by DTT eluting after about 15 min in the current phase system whereas AA already elutes after less than 3 min. Uric acid is usually present in the chromatograms but does not interfere.

### Method

Blood samples of at least 1 ml are centrifuged and 0.2 ml of the supernatant is thoroughly mixed with 0.9 ml MPA (3%) and immediately frozen ( $-20^{\circ}\text{C}$ ). After thawing, 0.2 ml phosphate buffer (pH 7.4) with a known amount of DTT is added, mixed and left for 30 min. If samples are not stored 0.2 ml sample is mixed with 0.2 ml of the phosphate/DTT mixture and left for 30 min. Then these nonstored samples are mixed with 0.9 ml MPA 3%. Subsequently, both types of samples are centrifuged (5 min, 10,000 g), 0.1 ml is transferred to the LC sample vials containing 0.9 ml MPA 3% and mixed. A volume of 10  $\mu\text{l}$  of this mixture is injected into the LCEC system.

Table 9

Set-up	
Column	Supelco C18-BDS, 5 $\mu\text{m}$ , 150 x 4.6 mm
Flow rate	1.3 ml/min
Mobile phase	Phosphate buffer (50 mM), pH 2.8, 200 mg/l EDTA, 2% methanol (v/v)
Sample	10 $\mu\text{l}$ inj.
Temperature	30°C
I cell	ca. 0.4 nA
E-cell	600 mV vs. Ag/AgCl sat'd




Figure 11: Chromatogram of ascorbic acid (1) in pretreated plasma. Plasma concentration is 41  $\mu\text{mol/l}$ . Other peaks are: Urate (2), Hydrochinon (IS, 3) and DTT (4). Courtesy: M. van der Horst, M.G.J. Lunenburg and E. Oeben, Scheper Ziekenhuis, Emmen, The Netherlands.

### References

1. S.A. Margolis and T.P. Davis, Clin. Chemistry, 34 (1988) 2217 – 2223.
2. S.A. Margolis, R.C. Paule and R.G. Ziegler, Clin. Chemistry, 36 (1990) 1750 – 1755.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4120	SenCell 2 mm GC sb





## Q10, ubiquinols, vitamin E, and $\beta$ -carotene in human LDL

### Introduction

Coenzyme Q10 is one of a number of naturally occurring ubiquinones that act as electron acceptors in mitochondrial oxidative phosphorylation. The reduced forms, the ubiquinols, are strong anti-oxidants. Also, oxidation of LDL (low-density lipoproteins) is believed to play an important role in early atherosclerosis. According to this oxidation hypothesis LDL is protected against oxidative stress by i.a. the Q10 antioxidants, thereby slowing down the formation of modified LDL. More specifically, the potent lipophilic antioxidants -TOH (tocopherol, vitamin E), QH2-10 (ubiquinol-10, the reduced form of ubiquinone-10 or Q10), -carotene and lycopene are supposed to be the important factors in this protection process. There is no unanimity about the relative physiological importance of these compounds.


The analysis by liquid chromatography with oxidative electrochemical detection (LC-EC) is very attractive because of its sensitivity and selectivity for the reduced compounds. However, due to the high lipophilicity of the compounds of interest very high modifier concentrations are required in the mobile phase putting specific demands to the LC-EC analysis to maintain sufficient electrical conductivity of the mobile phase. The method described here provides the conditions required. Detailed data regarding the method are given in [1].

### Method

Blood samples were collected into evacuated tubes containing K3-EDTA and placed on ice in the dark. Within 2 hours the plasma was separated by centrifugation. Subsequently, ultracentrifugation was performed to isolate the LDL. Prior to extraction BHT (butylated hydroxytoluene) as antioxidant (250  $\mu$ g/ml) was added and all treatments were done in a nitrogen

atmosphere. Samples (200  $\mu$ l) were mixed with 2 ml methanol, 4 ml hexane was added, vortex mixed, centrifuged, the hexane layer collected and the procedure was repeated.

The 2 hexane layers were pooled, dried with nitrogen, the residue stored at  $-20^{\circ}\text{C}$  and dissolved in mobile phase just prior to analysis. See [1] for further details.



**Figure 14:** Analysis of human LDL. Concentrations (amounts) are: 1. a-tocopherol (vitamin E) 3.6  $\mu\text{mol/l}$  (72.9 pmol), 2. ubiquinol-9 0.77  $\mu\text{mol/l}$  (15.5 pmol), 3. ubiquinol-10 0.21  $\mu\text{mol/l}$  (4.2 pmol), and 4. b-carotene 0.11  $\mu\text{mol/l}$  (2.2 pmol). The range is programmed at 10 (t=0), 1 (a), 0.5 (b), 1 (c) and 10 nA/V (d). Courtesy ref [1].

### References

- Yolanda B. de Rijke et al., *Arterioscler. Thromb. Vasc. Biol.* 17 (1997) 127-133

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4320	SenCell 2 mm GC HyREF

**Table 11**

Set-up	
Column	Inertsil ODS-2, 5 $\mu\text{m}$ , 200 x 3 mm
Flow rate	0.35 mL/min
Sample	20 $\mu\text{l}$ extracted from human plasma
Mobile phase	22.5% methanol, 77.5 % ethanol/isopropanol (95/5), 20 mM LiClO <sub>4</sub>
Temperature	30 $^{\circ}\text{C}$ for column and flow cell
E-cell	600 mV vs. Ag/AgCl (sat'd with LiCl)



## Fat soluble Vitamins A, D, E, K

### Introduction

Vitamins A, D, E and K belong to the fat soluble vitamins. These vitamins are involved in several biochemical processes in the body. Briefly, **vitamin A** (retinol) plays a role in vision and bone growth. It comes from animal sources such as eggs, meat and dairy products. Beta-carotene, a precursor, comes from fruit and vegetables (paprikas, carrots).

**Vitamin D** (ergocalciferol, D2, cholecalciferol, D3) promotes the adsorption of calcium in the body, essential to development of bones and teeth. Vitamin D is made by the body when exposed to sun light, or via our diet of cheese, butter, fish, and milk.

Tocopherol, or **Vitamin E**, is an important antioxidant. Antioxidants protect cells against the effects of free radicals, which are potentially damaging by-products of the body's metabolism.

**Vitamin K** denotes a group of 2-methilo-naphthoquinone derivatives. They are needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. Normally it is produced by bacteria in the intestines.

### Method

The HPLC system consists of reversed phase column and a apolar mobile phase (Table I). For EC detection an electrolyte is required therefore lithium perchlorate was added to the mobile phase. A VT03 cell with glassy carbon electrode has been used. Under these extremely apolar conditions the HyREF is the best choice for a reference electrode.

Only when Vitamin K must be analysed a second pre-reduction cell is applied.

Table 12

Set-up	
Column	Spherisorb ODS 100 x 4.6 mm, 3 µm
Flow rate	1.0 mL/min
Sample	Vitamins A and A acetate: 5 µM, E: 10 µM, D2, D3, K1, K2: 100 µM
Mobile phase	100 mmol/l lithium perchlorate, 96 % MeOH
Temperature	30 °C for column and flow cell
E-cell	1050 mV vs. Hy-REF, Only for vit K: pre-reduction: -400 mV




Figure 15: Analysis of vitamin A (1), vitamin A acetate (2), vitamin D2 (3), vitamin D3 (4), vitamin E (5), vitamin K2 (6) and vitamin K1(7). Scale: 240 nA full scale.

### Recommendation

The advised configuration for this application is the ALEXYS Analyzer using an autosampler with sample cooling option.

### Ordering information

180.0039W	ALEXYS Clinical Analyzer
116.4320	SenCell 2 mm GC HyREF



*For research purpose only.* The information shown in this communication is solely to demonstrate the applicability of the ALEXYS system. The actual performance may be affected by factors beyond Antec's control. Specifications mentioned in this application note are subject to change without further notice.

**Antec Scientific (USA)**  
info@AntecScientific.com  
www.AntecScientific.com  
T 888 572 0012

**Antec Scientific (worldwide)**  
info@AntecScientific.com  
www.AntecScientific.com  
T +31 71 5813333

